MedTrace Logo

Progesterone for the Treatment of Cocaine Dependence - 1

NCT00218257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2020-10-08

Study results available
· View outcomes & findings →

Summary

Past research has demonstrated that cocaine dependent women experience less severe responses to cocaine during the luteal phase of the menstrual cycle, when estrogen and progesterone concentrations are high. The purpose of this study is to determine whether administered progesterone reduces subjective and physiological responses to cocaine in cocaine dependent individuals.

Conditions

  • Cocaine Abuse
  • Cocaine-Related Disorders

Interventions

DRUG

Progesterone

200mg progesterone twice daily

OTHER

Placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Sheila M. Specker, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
46 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2008-04-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00218257 on ClinicalTrials.gov